Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Genitourinary tumours, prostate

3619 - Preliminary results from TRITON2: a phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Date

21 Oct 2018

Session

Poster Discussion session - Genitourinary tumours, prostate

Presenters

Wassim Abida

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

W. Abida1, A.H. Bryce2, N.J. Vogelzang3, R.J. Amato4, I. Percent5, J.D. Shapiro6, R. McDermott7, A. Hussain8, A. Patnaik9, D. Petrylak10, C.J. Ryan11, T. Stanton12, J. Zhang13, A.D. Simmons14, D. Despain15, M. Collins16, T. Golsorskhi17, H.I. Scher1, S. Chowdhury18

Author affiliations

  • 1 Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Hematology/oncology, Mayo Clinic, 85054 - Phoenix/US
  • 3 Medical Oncology, Comprehensive Cancer Centers of Nevada, 89169 - Las Vegas/US
  • 4 Oncology, UT Health Science Center, 77030 - Houston/US
  • 5 Medical Oncology, Florida Cancer Specialists, Port Charlotte/US
  • 6 Medical Oncology, Cabrini Hospital, 3186 - Malvern/AU
  • 7 Genito-urinary Oncology, Adelaide and Meath Hospital (Incorporating the National Children's Hospital), 24 - Dublin/IE
  • 8 Department Of Medicine, University of Maryland Greenebaum Cancer Center, Baltimore/US
  • 9 Medical Oncology, University of Chicago Comprehensive Cancer Center, 60637 - Chicago/US
  • 10 Medical Oncology, Yale University, Yale Cancer Center, 06520-8032 - New Haven/US
  • 11 Department Of Medicine, University of Minnesota, Minneapolis/US
  • 12 Medical Oncology, St. Joseph Health Cancer Center, Santa Rosa/US
  • 13 Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa/US
  • 14 Translational Medicine, Clovis Oncology, Inc., 94158 - Boulder/US
  • 15 Biostatistics, Clovis Oncology, Inc., Boulder/US
  • 16 Study Operations, Clovis Oncology, Inc., Boulder/US
  • 17 Clinical Development, Clovis Oncology, Inc., Boulder/US
  • 18 Medical Oncology, Guy's Hospital and Sarah Cannon Research Institute, SE1 9RT - London/GB
More

Resources

Abstract 3619

Background

Treatment options for mCRPC following androgen deprivation and taxane therapy are limited. Preclinical and limited clinical data suggest efficacy of PARP inhibition in HRR-deficient PCa.

Methods

TRITON2 (NCT02952534; target enrolment, 157 pts) is evaluating rucaparib 600 mg BID in pts with a deleterious germline or somatic alteration in BRCA1, BRCA2 or 1 of 13 other prespecified HRR genes. Pts who progressed on 1–2 lines of androgen receptor–directed therapy and 1 prior line of taxane-based chemotherapy for mCRPC are eligible. The primary endpoint is centrally assessed confirmed objective response rate per modified RECIST v1.1/PCWG3 for pts with measurable disease and confirmed prostate-specific antigen (PSA) response (≥50% decrease) in pts without measurable disease. PSA response in all pts is a secondary endpoint.

Results

At the 6 Mar 2018 data cutoff date, 52 pts were treated with rucaparib. Median duration of follow-up was 3.7 mo (range, 1.0–12.6). Twenty-six pts (50%) had a BRCA1/2 alteration (BRCA pts), 12 had a CDK12 alteration, 10 had an ATM alteration and 4 had an alteration in another HRR gene. Prior therapies included docetaxel (88.5%), enzalutamide (82.7%), abiraterone (71.2%) and cabazitaxel (11.5%). Forty-four pts (84.6%) had bone metastases; 33 (63.5%) and 17 pts (32.7%) had nodal and visceral metastases, respectively. Among BRCA pts, 21 (80.8%) remain on study (median treatment duration, 16.1 wk; range, 4.1–36.9). Eleven of 23 evaluable BRCA pts had a confirmed PSA response (47.8%; 95% CI, 26.8–69.4). Five of 11 evaluable BRCA pts had a confirmed investigator-assessed RECIST/PCWG3 response (45.5%; 95% CI, 16.7–76.6). Overall, the most common treatment-emergent adverse events (TEAEs) included nausea (48.1%; grade ≥3, 3.8%) and asthenia/fatigue (44.2%; grade ≥3, 1.9%). One (1.9%) pt discontinued due to a TEAE; no deaths were reported.

Conclusions

Rucaparib has encouraging antitumour activity in mCRPC pts with a deleterious alteration in BRCA1 or BRCA2. Updated data from current and newly enrolled pts will be presented, including from pts with other gene alterations.

Clinical trial identification

NCT02952534.

Legal entity responsible for the study

Clovis Oncology, Inc.

Funding

Clovis Oncology, Inc.

Editorial Acknowledgement

Writing and editorial support, funded by Clovis Oncology, Inc. (Boulder, CO, USA) was provided by Nathan Yardley, PhD, and Shannon Davis of Ashfield Healthcare Communications (Middletown, CT, USA).

Disclosure

W. Abida: Consulting, Advisory role: Clovis Oncology; Honoraria: Caret Healthcare; Research funding: AstraZeneca, Zenith Epigenetics. N.J. Vogelzang: Consulting, Advisory role: Caris, Sanofi Aventis, Bayer, Pfizer, Janssen, AstraZeneca, Astellas; Stock options owner: Caris; Editor: Up-To-Date. R.J. Amato: Consulting, Advisory role, Speaker bureaus: Jansen, Astellas/Pfizer (Medivation), Novartis. A. Hussain: Consulting, Advisory role: Bayer, Bristol-Myers Squibb, AstraZeneca. A. Patnaik: Consulting, Advisory role: Janssen; Research funding: Bristol-Myers Squibb, GlaxoSmithKline. D. Petrylak: Consulting, Advisory role: Bayer, Bellicum Pharmaceuticals, Dendreon, Johnson & Johnson, Exelixis, Ferring, Millenium, Medivation, Pfizer, Roche, Sanofi and Tyme Pharmaceuticals; Expert testimony: Celgene, Sanofi; Research funding: Oncogenex, Progenics, Johnson & Johnson, Dendreon, Sanofi, Endocyte, Genentech, Merck, Astellas Medivation, Novartis, Agensys, AstraZeneca, Bayer, Lilly, Innocrin Pharma, MedImmune, Millineum, Pfizer, Roche, Sotio; Stock owner, Other ownership interests: Bellicum Pharmaceuticals and Tyme, Inc. C.J. Ryan: Consulting, Advisory role: Bayer, Millennium; Honoraria: Janssen Oncology, Astellas Pharma; Research funding: BIND Biosciences, Karyopharm Therapeutics, Novartis. J. Zhang: Consulting, Advisory role, Speaker’s bureaus: AstraZeneca, Sanofi; Research funding: AstraZeneca, Astellas Pharma, Bayer. A.D. Simmons, D. Despain, M. Collins, T. Golsorskhi: Employee, Stock owner, Stock option owner: Clovis Oncology. H.I. Scher: Consulting, Advisory role: AstraZeneca, Astellas Pharma, Bristol-Myers Squibb, Celgene, Endocyte, Exelixis, Endo Pharmaceuticals, Ferring, Foundation Medicine, Genentech, Janssen, OncologySTAT, Palmetto GBA, Pfizer, Sanofi, Takeda, Ventana Medical Systems, BIRB-Copernicus Group, Medivation; Speaker’s bureau: WebMD; Travel, accommodation: Exelixis, Janssen, Sanofi, Endocyte, AstraZeneca, Genentech, Bristol-Myers Squibb, Celgene, Pfizer, Takeda, Ferring, WIRB-Copernicus Group, and Astellas Pharma; Honoraria: Chugai Pharma; Research funding: BIND Biosciences, Exelixis, Janssen, Medivation, Janssen Diagnostics. S. Chowdhury: Consulting, Advisory role, Speaker’s bureaus: Clovis Oncology, Sanofi, Pfizer, Astellas Pharma, Janssen; Honoraria: GlaxoSmithKline, Novartis; Research funding: Sanofi, Johnson & Johnson. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.